The Application of Control Charts in Regulated Bioanalysis for Monitoring Long-Term Reproducibility

References

• Guideline on Bioanalytical Method Validation, European Medicines Agency (2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
   Google Scholar
• Guidance for Industry – Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (2001). www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.
   Google Scholar
• Lee JW , DevanarayanV, BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23 (2), 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• ICH M4E Guideline: Clinical Overview and Clinical Summary of Module 2 and Module 5: Clinical Study Reports (R1) [cited 2002 Sep 12]. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4__R1__Efficacy/M4E__R1_.pdf.
   Google Scholar
• Lalonde RI , KowalskiKG, Hutmacheret al. Model-based drug development. Clin. Pharmacol. Therap. 82 (1), 21–21 (2007).
   PubMed Web of Science ®Google Scholar
• Laporte-Simitsidis S , GirardP, MismettiP, ChabaudS, DecoususH, BoisselJP. Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?J. Pharm. Sci. 89 (2), 155–167 (2000).
   PubMed Web of Science ®Google Scholar
• Shewhart WA . Economic Control Of Quality Of The Manufactured Product. D. Van Nostrand Company, Inc., NY, USA (1931).
   Google Scholar
• Levey S , JenningsER. The use of control charts in the clinical laboratory. Am. J. Clin. Pathol. 20, 1059–1066 (1950).
   PubMed Web of Science ®Google Scholar
• Burtis CA , AshwoodER, BrunsDE (Eds). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (4th Edition). Elsevier Saunders, St Louis, MO, USA (2006).
   Google Scholar
• Westgard JO , BarryPL, HuntMR, GrothT. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin. Chem. 27 (3), 493–501 (1981).
   PubMed Web of Science ®Google Scholar
• Huang Y , ShiR, GeeW, BonderudR. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug monitoring. Bioanalysis4 (15), 1919–1931 (2012).
   PubMed Web of Science ®Google Scholar
• Verch T . Application of quality by design and statistical quality control concepts in immunoassays. Bioanalysis6 (23), 3251–3260 (2014).
   PubMed Web of Science ®Google Scholar
• Geist BJ , EganAC, YangTY, DongY, ShankarG. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. Bioanalysis5 (2), 227–244 (2013).
   PubMed Web of Science ®Google Scholar
• King LE , FarleyE, ImazatoMet al. Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 16 (3), 504–515 (2014).
   PubMed Web of Science ®Google Scholar
• Jenkins RJ . Accuracy: a potential quandary in regulated bioanalysis of ‘endogenous’ analytes. Bioanalysis8 (23), 2393–2397 (2016).
   PubMed Web of Science ®Google Scholar
• Arnold ME , BoothB, KingLet al. Workshop Report: Crystal City VI – Bioanalytical method validation for biomarkers. AAPS J. 18 (6), 1366–1372 (2016).
   PubMed Web of Science ®Google Scholar
• Wang J , LeeJW, BurnsDet al. “Fit-for-Purpose” method validation and application of a biomarker (C-terminal telopeptides of Type 1 collagen) in denosumab clinical studies. AAPS J. 11 (2), 385–394 (2009).
   PubMed Web of Science ®Google Scholar
• Figurski MK , WaligórskaT, ToledoJet al. Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative Study patients. Alzheimers Dement. 8, 250–260 (2012).
   PubMed Web of Science ®Google Scholar
• Zelena E , DunnWB, BroadhurstDet al. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 81, 1357–1364 (2009).
   PubMed Web of Science ®Google Scholar
• Causey AG , HillHM, PhillipsLJ. Evaluation of criteria for the acceptance of bioanalytical data. J. Pharm. Biomed. Anal. 8 (8–12), 625–628 (1990).
   PubMed Web of Science ®Google Scholar
• Wille SMR , PetersFT, Di FazioV, SamynN. Practical aspects concerning validation and quality control for forensic and clinical bioanalytical quantitative methods. Accred. Qual. Assur. 16, 279–292 (2011).
   Web of Science ®Google Scholar
• Lowes S , LeLacheurR, ShoupRet al. Recommendations on incurred sample stability (ISS) by GCC. Bioanalysis6 (19), 2385–2390 (2014).
   PubMedGoogle Scholar
• Kringle RO . An assessment of the 4–6–20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharm. Res. 11 (4), 556–560 (1994).
   PubMed Web of Science ®Google Scholar
• Jian W , EdomRW, WengN. Important considerations for quantitation of small-molecule biomarkers using LC-MS. Bioanalysis4 (20), 2431–2434 (2012).
   PubMed Web of Science ®Google Scholar
• Stevensson LF , PurushothamaS. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. Bioanalysis6 (2), 185–198 (2014).
   PubMed Web of Science ®Google Scholar
• Fraser S , FleenerC, OgborneK, SoderstromC. When close is not close enough: a comparison of endogenous and recombinant biomarker stability samples. Bioanalysis7 (11), 1355–1360 (2015).
   PubMed Web of Science ®Google Scholar
• OECD . OECD series on principles of good laboratory practice and compliance monitoring. Number 1. OECD principles on good laboratory practice (as revised in 1997). 1–39 (1998). www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm.
   Google Scholar
• Timmerman P , HerlingC, StoellnerDet al. European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. Bioanalysis4 (15), 1883–1894 (2012).
   PubMed Web of Science ®Google Scholar
• White S , DunnJ, SummerfieldS. The quest for assay robustness across the life cycle of a bioanalytical method. Bioanalysis7 (7), 815–824 (2015).
   PubMed Web of Science ®Google Scholar
• Yadav MS , ShrivastavPS, De BoerT, WielingJ, SinghalP. Current understanding of bioanalytical assay reproducibility: incurred sample reanalysis, incurred sample stability and incurred sample accuracy. In : Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations. LiW, ZhangJ, TseFLS ( Eds). John Wiley & Sons, Inc., NJ, USA (2013).
   Google Scholar
• Rorabacher DB . Statistical treatment for rejection of deviant values: critical values of Dixon’s “Q” parameter and related subrange ratios at the 95% confidence level. Anal. Chem. 63 (2), 139–149 (1991).
   Web of Science ®Google Scholar
• Berg DK . New neuronal growth factors. Ann. Rev. Neurosci. 7, 149–170 (1984).
   PubMed Web of Science ®Google Scholar
• Ueda N , TakasawaK. Role of hepcidin-25 in chronic kidney disease: anemia and beyond. Curr. Med. Chem. 24, 1417–1452 (2017).
   PubMed Web of Science ®Google Scholar
• Laarakkers CMM , WiegerinckET, KlaverSet al. Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS ONE8 (10), e77518 (2013).
   PubMed Web of Science ®Google Scholar
• Wieling J . Robust, fit-for-purpose method transfer: why we should apply equivalence testing. Bioanalysis7 (7), 807–814 (2015).
   PubMed Web of Science ®Google Scholar
• Timmerman P , WhiteS, McDougallSet al. Tiered approach into practice: scientific validation for chromatography-based assays in early development – a recommendation from the European Bioanalysis Forum. Bioanalysis7 (18), 2387–2398 (2015).
   PubMed Web of Science ®Google Scholar